



OPEN ACCESS

EDITED AND REVIEWED BY
Adam Wheatley,
The University of Melbourne, Australia

*CORRESPONDENCE

Oriol Bestard
✉ oriol.bestard@vallhebron.cat

†These authors have contributed
equally to this work and share
first authorship

‡These authors share senior authorship

RECEIVED 11 June 2024

ACCEPTED 19 June 2024

PUBLISHED 01 July 2024

CITATION

Pernin V, Meneghini M, Torija A, Jouve T,
Del Bello A, Sanz-Muñoz I, Eiros JM,
Donadeu L, Polo C, Morandeira F, Navarro S,
Masuet C, Favà A, LeQuintrec M, Kamar N,
Crespo E and Bestard O (2024) Corrigendum:
Impaired antigen-specific B-cell responses
after Influenza vaccination in kidney
transplant recipients receiving co-stimulation
blockade with Belatacept.
Front. Immunol. 15:1447503.
doi: 10.3389/fimmu.2024.1447503

COPYRIGHT

© 2024 Pernin, Meneghini, Torija, Jouve,
Del Bello, Sanz-Muñoz, Eiros, Donadeu, Polo,
Morandeira, Navarro, Masuet, Favà, LeQuintrec,
Kamar, Crespo and Bestard. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

Vincent Pernin^{1†}, Maria Meneghini^{2,3†}, Alba Torija³,
Thomas Jouve^{3,4}, Arnaud Del Bello⁵, Iván Sanz-Muñoz⁶,
Jose Maria Eiros⁷, Laura Donadeu³, Carol Polo⁸,
Francisco Morandeira⁹, Sergio Navarro⁹, Cristina Masuet¹⁰,
Alexandre Favà⁸, Moglie LeQuintrec¹, Nassim Kamar⁴,
Elena Crespo^{3‡} and Oriol Bestard^{2,3*‡}

¹Kidney Transplant Unit, Nephrology Department, Montpellier University Hospital, Montpellier, France,

²Kidney transplant Unit, Nephrology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain, ³Laboratory of Nephrology and Transplantation, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Kidney transplant Unit, Nephrology Department, Grenoble University Hospital, Grenoble, France, ⁵Centro Nacional de Gripe de Valladolid, Universidad de Valladolid, Valladolid, Spain, ⁶Centro Nacional de Gripe, Valladolid Universidad de Valladolid, Valladolid, Spain,

⁷Department of Microbiology and Parasitology, Rio Hortega University Hospital, University of Valladolid, Valladolid, Spain, ⁸Kidney Transplant Unit, Nephrology Department, Bellvitge University Hospital, Barcelona, Spain, ⁹Immunology Department, Bellvitge University Hospital, Barcelona, Spain,

¹⁰Department of Preventive Medicine, Bellvitge University Hospital, Barcelona, Spain

KEYWORDS

kidney transplantation, co-stimulation blockade, memory B cells, influenza vaccination, calcineurin inhibitors, T follicular helper (Tfh) cell

A Corrigendum on

Impaired antigen-specific B-cell responses after Influenza vaccination in kidney transplant recipients receiving co-stimulation blockade with Belatacept

by Pernin V, Meneghini M, Torija A, Jouve T, Del Bello A, Sanz-Muñoz I, Eiros J M, Donadeu L, Polo C, Morandeira F, Navarro S, Masuet C, Favà A, LeQuintrec M, Kamar N, Crespo E and Bestard O (2022). *Front. Immunol.* 13:918887. doi: 10.3389/fimmu.2022.918887

In the published article, there was an error in **Table 1** as published. While it stated that 3 (33%) patients received the “Chiromas” vaccine, the correct information is that 3 (33%) patients in the belatacept group received the “Vaxigrip” vaccine. The corrected **Table 1** and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Main characteristics of the study population.

	Belatacept (n=9)	Tacrolimus (n=14)	p value
Time after transplantation (years)	9.67 ± 4.19	3.5 ± 4.27	0.003
Recipient age (years)	60.8 ± 10.3	54.9 ± 12.3	0.25
Recipient gender (Male) (n, %)	8 (89%)	9 (64%)	0.34
Donor age (years)	60.2 ± 17.5	54.8 ± 13.4	0.51
Transplant type			0.82
Living (n, %)	1 (11%)	1 (7%)	
DBD/DCD (n, %)	6 (67%)/2 (22%)	11 (79%)/2 (14%)	
Transplant number (1 st) (n, %)	7 (78%)	10 (83%)	0.48
Time on dialysis (months)	17.8 ± 18.3	34.3 ± 25	0.18
Cause of ESRD (n, %)			0.47

(Continued)

TABLE 1 Continued

	Belatacept (n=9)	Tacrolimus (n=14)	p value
Glomerular diseases	4 (44%)	5 (36%)	
Diabetic nephropathy	0	1 (7%)	
Polycystic kidney disease	1 (11%)	3 (21%)	
Vascular/Hypertension	1 (11%)	2 (14%)	
Others	3 (33%)	1 (7%)	
Unknown	0	2 (14%)	
Relevant comorbidities (n, %)			
Diabetes	0	2 (15%)	0.49
Hypertension	6 (67%)	11 (85%)	0.61
Heart failure	1 (11%)	2 (15%)	1
Previous splenectomy	0	0	
Induction treatment (n, %)			0.39
None	1 (14%)	0	
Basiliximab	7 (78%)	11 (79%)	
rATG	1 (14%)	3 (21%)	
MMF dose (mg/d)	826 ± 332	881 ± 227	0.66
Prior anti-flu vaccination (n, %)	7 (78%)	12 (86%)	1
Type of vaccination (Vaxigrip)	3 (33%)	0	0.047
cPRA at time of vaccination (%)	10.2 ± 31	10.9 ± 22	0.95
DSA at time of vaccination (n, %)	0	2 (14%)	0.17
<i>De novo</i> DSA after vaccination (n, %)	0	0	1
Acute rejection prior to vaccination (n, %)	1 (12.5%)	2 (13%)	1
Acute rejection after vaccination (n, %)	0	0	1
eGFR at time of vaccination (mL/min/1.73m ²)	54.9 ± 22	63.9 ± 15	0.34